China Imatinib Mesylate Market

The mortality of leukemia ranks sixth among tumors while its incidence and mortality ranks first among malignant tumors for teenagers.

The incidence of leukemia reaches two age peaks: 0-9 years old and above 60 years old. Maintain Messmate was a tyrosine kinas inhibitor developed by Innovation. On May. 10, 001, Maintain Messmate got Fad’s express approval with the trade name of Clever due to its groundbreaking anti-tumor mechanism. On Deck. 23, 2009, Maintain Messmate gained its status as the first-line treatment for chronic unloosens leukemia under Fad’s approval.

And now it has been approved for treatment of chronic unloosens leukemia in more than 80 countries around the world. View Full Report at: http://www. Nonrepresentational. Biz/analysis/289058 After entering Chinese market on Par. 17, 2002, Maintain Messmate has developed fast with annual sales reaching CCNY 532 million in 2014 and CARR reaching up to 42% during he period of 20052014. Currently, Maintain Messmate in the Chinese market is made by the following three companies: Innovation (Swiss), Chic ATA Attaining Pharmaceutical Group Co. Ltd and Hanson Pharmaceutical, among which Innovation has the largest market share of over 98% with sales value reaching up to CCNY 523 million in 2014. Maintain Messmate has accurate curative effects

on chronic unloosens leukemia despite its relatively high price. Chinese patients with low incomes were once sued for purchasing Maintain Messmate smuggled from India whose price is only 10% or less of that in Chinese market. As China’s economy develops, people’s income and purchasing power increases.